<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Panobinostat (United States: Withdrawn from market): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet"/></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Panobinostat (United States: Withdrawn from market): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Panobinostat (United States: Withdrawn from market): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="100322" href="/d/html/100322.html" rel="external">see "Panobinostat (United States: Withdrawn from market): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F27258054"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Gastrointestinal events:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Severe diarrhea occurred in 25% of panobinostat treated patients. Monitor for symptoms, institute antidiarrheal treatment, interrupt panobinostat, and then reduce dose or discontinue panobinostat.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular events:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Severe and fatal cardiac ischemic events, severe arrhythmias, and ECG changes have occurred in patients receiving panobinostat. Arrhythmias may be exacerbated by electrolyte abnormalities. Obtain ECG and electrolytes at baseline and periodically during treatment as clinically indicated.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F27379821"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Farydak [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F27258056"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Histone Deacetylase (HDAC) Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F27628362"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> In December 2021, the manufacturer voluntarily withdrew the approval of panobinostat for the treatment of relapsed or refractory multiple myeloma (in combination with bortezomib and dexamethasone) from the US market.</p>
<p style="text-indent:-2em;margin-left:2em;">Baseline ANC should be ≥1,500/mm<sup>3</sup> and platelets ≥100,000/mm<sup>3</sup> prior to treatment. Do not initiate panobinostat in patients with a QTcF &gt;450 msec, clinically significant baseline ST-segment depression or T-wave abnormalities, or a history of recent myocardial infarction or unstable angina.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f1c12cde-98c7-41e9-80b8-0893e9934cc7">Multiple myeloma, relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma, relapsed/refractory:</b>
<b>Oral: </b>20 mg once every other day for 3 doses each week during weeks 1 and 2 of a 21-day treatment cycle (eg, Monday, Wednesday, and Friday of weeks 1 and 2 only, rest during week 3) for up to 8 cycles (in combination with bortezomib and dexamethasone); treatment may continue (the same schedule for panobinostat; bortezomib and dexamethasone schedules are modified) for an additional 8 cycles in patients experiencing clinical benefit and acceptable toxicity (San-Miguel 2014). The total duration of therapy may be up to 16 cycles (48 weeks) <b>or</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Heavily pretreated bortezomib-refractory patients:</i>
<b>Oral: </b>20 mg three days/week on weeks 1 and 2 of a 3-week treatment cycle for up to 8 cycles (in combination with bortezomib and dexamethasone); treatment may continue (the same schedule for panobinostat; bortezomib and dexamethasone schedules are modified) until disease progression or unacceptable toxicity (Richardson 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label combinations:</i>
<b>Oral:</b> 20 mg on days 1, 3, 5, 15, 17, and 19 of a 28-day cycle (in combination with carfilzomib) until disease progression or unacceptable toxicity (Berdeja 2021) <b>or</b> 20 mg on days 1, 3, 5, 15, 17, and 19 of a 28-day cycle (in combination with lenalidomide and dexamethasone) (Chari 2017).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed doses:</i> A missed dose may be taken up to 12 hours after the scheduled time. If vomiting occurs, do not repeat the dose; resume with the next usual scheduled dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult Drug Interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991308"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;80 mL/minute: There are no dosage adjustments provided in the manufacturer’s labeling. However, no need for dosage adjustment is expected (Krens 2019). Based on a pharmacokinetic study of a single 30 mg dose, renal impairment does not appear to impact panobinostat exposure in patients with mild, moderate, and severe renal impairment (excluding dialysis patients), and initial dosage adjustment is not necessary (Sharma 2015).</p>
<p style="text-indent:-2em;margin-left:2em;">End-stage renal disease (ESRD) and ESRD on dialysis: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied). No need for dosage adjustment is expected (Krens 2019). Per the manufacturer, the dialyzability of panobinostat is unknown.</p></div>
<div class="block doha drugH1Div" id="F50988648"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic impairment <i>prior to </i> treatment:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment (bilirubin ≤1 times ULN and AST &gt;1 times ULN or bilirubin &gt;1 to 1.5 times ULN and any AST): Reduce initial dose to 15 mg; monitor frequently for adverse events and adjust dose as needed for toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate impairment (bilirubin &gt;1.5 to 3 times ULN and any AST): Reduce initial dose to 10 mg; monitor frequently for adverse events and adjust dose as needed for toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: Avoid use.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic impairment <i>during</i> treatment: If liver function tests are abnormal, consider dosage adjustments and monitor until liver function returns to normal or baseline.</p></div>
<div class="block dot drugH1Div" id="F27628368"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">If dose reductions are necessary, keep the same treatment schedule and reduce panobinostat dose in increments of 5 mg (from 20 mg to 15 mg, from 15 mg to 10 mg); if dose reduction below 10 mg 3 times a week is necessary, discontinue treatment.</p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:center;">
<b>Panobinostat Recommended Dose Modifications for Adverse Reactions</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Adverse reaction</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Severity</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose modification</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<b>Hematologic toxicity</b></p></td></tr>
<tr>
<td align="center" rowspan="4">
<p style="text-indent:0em;text-align:left;">Thrombocytopenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 3 (platelets &lt;50,000/mm<sup>3</sup>)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">No dosage adjustments are necessary; monitor platelets at least weekly.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 3 (platelets &lt;50,000/mm<sup>3</sup>) with bleeding</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Interrupt panobinostat treatment, monitor platelets at least weekly until ≥50,000/mm<sup>3</sup> and then restart panobinostat at a reduced dose.</p>
<p style="text-indent:0em;text-align:left;">Interrupt bortezomib until platelets ≥50,000/mm<sup>3</sup>; if only 1 bortezomib dose omitted, restart bortezomib at the same dose; if ≥2 consecutive doses or doses within the same cycle are omitted, then restart bortezomib at a reduced dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 4 (platelets &lt;25,000/mm<sup>3</sup>)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Interrupt panobinostat treatment, monitor platelets at least weekly until ≥50,000/mm<sup>3</sup> and then restart panobinostat at a reduced dose.</p>
<p style="text-indent:0em;text-align:left;">Interrupt bortezomib until platelets ≥50,000/mm<sup>3</sup>; if only 1 bortezomib dose omitted, restart bortezomib at the same dose; if ≥2 consecutive doses or doses within the same cycle are omitted, then restart bortezomib at a reduced dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Severe thrombocytopenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Consider platelet transfusions. Discontinue panobinostat if thrombocytopenia does not improve despite treatment modifications or if repeated platelet transfusions are required.</p></td></tr>
<tr>
<td align="center" rowspan="5">
<p style="text-indent:0em;text-align:left;">Neutropenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 3 (ANC 750 to 1,000/mm<sup>3</sup>)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">No dosage adjustments are necessary.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 3 (ANC 500 to 750/mm<sup>3</sup> [2 or more occurrences])</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Interrupt panobinostat treatment until ANC ≥1,000/mm<sup>3</sup> and then restart at the same dose.</p>
<p style="text-indent:0em;text-align:left;">Bortezomib dosage adjustment is not necessary.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 3 (ANC &lt;1,000/mm<sup>3</sup>) with neutropenic fever</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Interrupt panobinostat treatment until neutropenic fever resolves and ANC ≥1,000/mm<sup>3</sup> and then restart at a reduced dose.</p>
<p style="text-indent:0em;text-align:left;">Interrupt bortezomib until neutropenic fever resolves and ANC ≥1,000/mm<sup>3</sup>; if only 1 bortezomib dose omitted, restart bortezomib at the same dose; if ≥2 consecutive doses or doses within the same cycle are omitted, then restart bortezomib at a reduced dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 4 (ANC &lt;500/mm<sup>3</sup>)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Interrupt panobinostat treatment until ANC ≥1,000/mm<sup>3</sup> and then restart at a reduced dose.</p>
<p style="text-indent:0em;text-align:left;">Interrupt bortezomib until ANC ≥1,000/mm<sup>3</sup>; if only 1 bortezomib dose omitted, restart bortezomib at the same dose; if ≥2 consecutive doses or doses within the same cycle are omitted, then restart bortezomib at a reduced dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Neutropenia, grade 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Consider growth factor support and/or dose modification; if neutropenia does not improve despite dose modification or growth factor support, or if severe infection occurs, discontinue panobinostat.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Anemia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 3 (hemoglobin &lt;8 g/dL)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Interrupt panobinostat until hemoglobin ≥10 g/dL and then restart at a reduced dose.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<b>Nonhematologic toxicity</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Cardiovascular</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">QTcF increase to ≥480 msec</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Interrupt panobinostat treatment; correct electrolyte abnormalities. If QT prolongation does not resolve, permanently discontinue panobinostat.</p></td></tr>
<tr>
<td align="center" rowspan="4">
<p style="text-indent:0em;text-align:left;">Diarrhea</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">First sign of abdominal cramping, loose stools, or onset of diarrhea</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Begin antidiarrheal medication (eg, loperamide).</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 2 (moderate diarrhea; 4 to 6 stools per day)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Interrupt panobinostat until resolved and then restart at the same dose.</p>
<p style="text-indent:0em;text-align:left;">Consider interruption of bortezomib until resolved and then restart at the same dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 3 (severe diarrhea; ≥7 stools per day, IV fluids or hospitalization required)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Interrupt panobinostat treatment until resolved and then restart at a reduced dose.</p>
<p style="text-indent:0em;text-align:left;">Interrupt bortezomib until resolved and then restart at a reduced dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 4 (life-threatening)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Permanently discontinue panobinostat.</p>
<p style="text-indent:0em;text-align:left;">Permanently discontinue bortezomib.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Infection</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Any</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Consider interrupting or discontinuing panobinostat. Do not initiate panobinostat if active infection is present.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Severe</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Discontinue panobinostat.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Nausea or vomiting</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Severe nausea (grades 3/4)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Interrupt panobinostat treatment until resolved and then restart at a reduced dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Severe/life-threatening vomiting (grades 3/4)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Interrupt panobinostat treatment until resolved and then restart at a reduced dose.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Other toxicities</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 3 or 4 toxicity or recurrent grade 2 toxicity</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold panobinostat treatment until recovery to grade 1 or less and then restart at a reduced dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Recurrent grade 3 or 4 toxicity</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold panobinostat treatment until recovery to grade 1 or less and then restart at a reduced dose.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F27628363"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F27637066"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not always defined.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Abnormal T waves on ECG (40%), peripheral edema (29%; grades 3/4: 2%), depression of ST segment on ECG (22%), cardiac arrhythmia (12%; grades 3/4: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Fatigue (≤60%, grades 3/4: ≤25%), lethargy (≤60%; grades 3/4: ≤25%), malaise (≤60%; grades 3/4: ≤25%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypocalcemia (67%; grades 3/4: 5%), hypoalbuminemia (63%; grades 3/4: 2%), hypophosphatemia (63%; grades 3/4: 20%), hypokalemia (52%; grades 3/4: 18%), hyponatremia (49%; grades 3/4: 13%), hyperphosphatemia (29%; grades 3/4: 2%), hypermagnesemia (27%; grades 3/4: 5%), weight loss (12%; grades 3/4: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (68%; grades 3/4: 25%), nausea (36%; grades 3/4: 6%), decreased appetite (28%; grades 3/4: 3%), vomiting (26%; grades 3/4: 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia (97%; grades 3/4: 67%), lymphocytopenia (82%; grades 3/4: 53%), leukopenia (81%; grades 3/4: 23%), neutropenia (75%; grades 3/4: 34%), anemia (62%; grades 3/4: 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hyperbilirubinemia (21%; grades 3/4: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Severe infection (31%; includes bacterial, fungal, and viral infections)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Weakness (≤60%; grades ≥3: ≤25%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (41%; grades 3/4: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (26%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (&gt;2% to &lt;10%), hypotension (&gt;2% to &lt;10%), orthostatic hypotension (&gt;2% to &lt;10%), palpitations (&gt;2% to &lt;10%), syncope (&gt;2% to &lt;10%), ischemic heart disease (4%), ECG changes, prolonged QT interval on ECG</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Chills (&gt;2% to &lt;10%), dizziness (&gt;2% to &lt;10%), headache (&gt;2% to &lt;10%), insomnia (&gt;2% to &lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cheilitis (&gt;2% to &lt;10%), erythema (&gt;2% to &lt;10%), skin lesion (&gt;2% to &lt;10%), skin rash (&gt;2% to &lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration (&gt;2% to &lt;10%), fluid retention (&gt;2% to &lt;10%), hyperglycemia (&gt;2% to &lt;10%), hyperuricemia (&gt;2% to &lt;10%), hypomagnesemia (&gt;2% to &lt;10%), hypothyroidism (&gt;2% to &lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention (&gt;2% to &lt;10%), abdominal pain (&gt;2% to &lt;10%), colitis (&gt;2% to &lt;10%), dysgeusia (&gt;2% to &lt;10%), dyspepsia (&gt;2% to &lt;10%), flatulence (&gt;2% to &lt;10%), gastritis (&gt;2% to &lt;10%), gastrointestinal pain (&gt;2% to &lt;10%), xerostomia (&gt;2% to &lt;10%), gastrointestinal toxicity</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary incontinence (&gt;2% to &lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemorrhage (grades 3/4: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis B (&gt;2% to &lt;10%), increased serum alkaline phosphatase (&gt;2% to &lt;10%), increased serum transaminases, increased serum bilirubin</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Sepsis (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Joint swelling (&gt;2% to &lt;10%), tremor (&gt;2% to &lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen (&gt;2% to &lt;10%), mean glomerular filtration rate decreased (&gt;2% to &lt;10%), renal failure (&gt;2% to &lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (&gt;2% to &lt;10%), dyspnea (&gt;2% to &lt;10%), rales (&gt;2% to &lt;10%), respiratory failure (&gt;2% to &lt;10%), wheezing (&gt;2% to &lt;10%)</p></div>
<div class="block coi drugH1Div" id="F27258059"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer’s labeling.</p></div>
<div class="block war drugH1Div" id="F27626066"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse events:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Hematologic toxicities, including severe thrombocytopenia, neutropenia, and anemia have occurred. Patients &gt;65 years of age may require more frequent monitoring.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular events: Severe and fatal cardiac ischemic events, severe arrhythmias, and ECG changes have occurred in patients receiving panobinostat. Arrhythmias may be exacerbated by electrolyte abnormalities. ECG abnormalities, including ST-segment depression and T-wave abnormalities, have been observed. Panobinostat may prolong the QT interval. Concomitant use with medications known to prolong the QT interval is not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI events: Severe diarrhea occurred in one-fourth of panobinostat-treated patients. Diarrhea (of any grade) was reported in over two-thirds of patients and may occur at any time. Patients should have antidiarrheal medications available for use; begin antidiarrheal medications at the first sign of diarrhea, loose stools, or abdominal cramping. If antiemetics are needed, some antiemetics known to prolong the QT interval (eg, dolasetron, ondansetron) may be used with frequent ECG monitoring.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemorrhage: Serious and fatal hemorrhage has occurred, including grade 3 or higher hemorrhage. All patients with hemorrhage also experienced thrombocytopenia at the time of hemorrhage.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Hepatic dysfunction (transaminase and total bilirubin elevations) has been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infection: Localized and systemic infections (including pneumonia, bacterial infections, invasive fungal infections, and viral infections) have been observed; infections may be severe (or fatal).</p></div>
<div class="block foc drugH1Div" id="F27379822"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Farydak: 10 mg [DSC] [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Farydak: 15 mg [DSC], 20 mg [DSC]</p></div>
<div class="block geq drugH1Div" id="F27379820"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F27658122"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Farydak Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $2,816.50</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $2,816.50</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $2,816.50</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F27628380"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer at approximately the same time on scheduled days. May administer with or without food. Swallow capsule whole with a cup of water. Do not open, crush, or chew the capsules. Avoid exposure to crushed and/or broken capsules. Avoid direct skin or mucous membrane contact with powder inside the capsules; if contact occurs, wash thoroughly.</p></div>
<div class="block hazard drugH1Div" id="F49104562"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block meg drugH1Div" id="F27393887"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.fda.gov%2Fdownloads%2FDrugs%2FDrugSafety%2FUCM436377.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn%2F8bxp4YrxUVJFUAWh6274giXB02SpqI6k0XJxfuS8JmZw%3D%3D&amp;TOPIC_ID=100045" target="_blank">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM436377.pdf</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F27258058"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma, relapsed or refractory:</b> Treatment of multiple myeloma (in combination with bortezomib and dexamethasone) in patients who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> In December 2021, the manufacturer voluntarily withdrew the approval of panobinostat for the treatment of relapsed or refractory multiple myeloma (in combination with bortezomib and dexamethasone) from the US market.</p></div>
<div class="block mst drugH1Div" id="F27626064"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Panobinostat may be confused with belinostat, palbociclib, pazopanib, ponatinib, tazemetostat, vorinostat</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its lists of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F27275646"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C19 (minor), CYP2D6 (minor), CYP3A4 (major), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2D6 (weak)</p></div>
<div class="block dri drugH1Div" id="F27275643"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing these oncologic agents several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Conivaptan: May increase the serum concentration of Panobinostat. Management: Reduce the panobinostat dose to 10 mg when it must be used with conivaptan. Monitor patient response to therapy closely for evidence of more severe adverse effects related to panobinostat therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Panobinostat.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Panobinostat.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Panobinostat. Management: Reduce the panobinostat dose to 10 mg when it must be used with a strong CYP3A4 inhibitor. Monitor patient response to therapy closely for evidence of more severe adverse effects related to panobinostat therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dolasetron: May enhance the arrhythmogenic effect of Panobinostat.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Granisetron: May enhance the arrhythmogenic effect of Panobinostat.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May increase the serum concentration of Panobinostat.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: May enhance the arrhythmogenic effect of Panobinostat.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pomegranate: May increase the serum concentration of Panobinostat.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Star Fruit: May increase the serum concentration of Panobinostat.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: Histone Deacetylase Inhibitors may enhance the adverse/toxic effect of Taurursodiol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: CYP2D6 Inhibitors (Weak) may increase the serum concentration of Thioridazine.  Management: Consider avoiding concomitant use of thioridazine and weak CYP2D6 inhibitors. If combined, monitor closely for QTc interval prolongation and arrhythmias. Some weak CYP2D6 inhibitors list use with thioridazine as a contraindication.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 3 after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F27626068"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Star fruit, pomegranate or pomegranate juice, and grapefruit or grapefruit juice may interfere with panobinostat metabolism. Management: Avoid star fruit, pomegranate or pomegranate juice, and grapefruit or grapefruit juice.</p></div>
<div class="block rep_considerations drugH1Div" id="F49309065"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Verify pregnancy status prior to use in patients who may become pregnant; pregnancy testing is recommended prior to use and intermittently during panobinostat therapy. Patients who may become pregnant should avoid pregnancy and use an effective contraceptive during therapy and for at least 3 months after the last panobinostat dose. Patients with partners who may become pregnant should use condoms during therapy and for at least 6 months after the last dose of panobinostat.</p></div>
<div class="block pri drugH1Div" id="F27620630"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on data from animal reproduction studies, in utero exposure to panobinostat may cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F27626065"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if panobinostat is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends a decision be made to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the person who is breastfeeding.</p></div>
<div class="block dic drugH1Div" id="F27628379"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Avoid star fruit, pomegranate or pomegranate juice, and grapefruit or grapefruit juice. </p></div>
<div class="block mop drugH1Div" id="F27628382"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">CBC with differential and platelets (prior to treatment initiation then weekly or more often if clinically indicated during treatment; monitor more frequently in patients ≥65 years of age); serum electrolytes, including potassium and magnesium prior to treatment and during treatment (in the clinical trial, electrolytes were monitored prior to the start of each cycle, after the fifth panobinostat dose in week 2 through cycle 8 and then at the beginning of cycles 9 to 16); liver function tests at baseline and regularly during treatment. Evaluate pregnancy status in patients who may become pregnant (rule out pregnancy prior to and intermittently during treatment). ECG (prior to treatment initiation and periodically as clinically indicated during treatment); monitor frequently if using concomitant medications known to prolong the QT interval). Monitor hydration status; monitor for gastrointestinal toxicity (eg, diarrhea, nausea, vomiting), signs/symptoms of hemorrhage and/or infection.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F27626070"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Panobinostat is a histone deacetylase (HDAC) inhibitor; it inhibits enzymatic activity of HDACs resulting in increased acetylation of histone proteins. Accumulation of acetylated histones and other proteins induces cell cycle arrest and/or apoptosis of some transformed cells. Panobinostat has minimal activity in multiple myeloma as a single-agent; however, synergistic activity is demonstrated when combined with bortezomib and dexamethasone (San-Miguel 2014).</p></div>
<div class="block phk drugH1Div" id="F27627044"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~90% to plasma proteins.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensive via reduction, hydrolysis, oxidation, and glucuronidation; CYP3A accounts for ~40 % of elimination, CYP2D6 and CYP2C19 are minor pathways.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~21%; AUC is 16% lower (compared with fasting) when administered with a high-fat meal.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~37 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Within 2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (44% to 77%; &lt;4% as unchanged drug); Urine (29% to 51%; &lt;3% as unchanged drug).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: ~160 L/hour.</p></div>
<div class="block phksp drugH1Div" id="F51192048"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: In patients with mild, moderate, and severe renal impairment, the AUC was 64%, 99%, and 59% of the normal renal function group, respectively.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: In patients with mild and moderate hepatic impairment, the AUC was increased 43% and 105%, respectively (compared with patients with normal hepatic function).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F45040419"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Farydak</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Farydak</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Farydak</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Farydak</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Farydak</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Farydak</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Farydak</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Farydak</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Farydak</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Farydak</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Farydak</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Ixapana</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Farydak</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Farydak</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Farydak</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Farydak</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Farydak</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Farydak</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Farydak</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Farydak</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Farydak</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Farydak</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Farydak</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33421178">
<a name="33421178"></a>Berdeja JG, Gregory TK, Faber EA, et al. A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma: final analysis of second dose-expansion cohort. <i>Am J Hematol.</i> 2021;9(4):428-435. doi:10.1002/ajh.26088<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/panobinostat-united-states-withdrawn-from-market-drug-information/abstract-text/33421178/pubmed" id="33421178" target="_blank">33421178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25710456">
<a name="25710456"></a>Berdeja JG, Hart LL, Mace JR, et al. Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma. <i>Haematologica.</i> 2015;100(5):670-676. doi:10.3324/haematol.2014.119735<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/panobinostat-united-states-withdrawn-from-market-drug-information/abstract-text/25710456/pubmed" id="25710456" target="_blank">25710456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29296798">
<a name="29296798"></a>Chari A, Cho HJ, Dhadwal A, et al. A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma. <i>Blood Adv.</i> 2017;1(19):1575-1583. doi:10.1182/bloodadvances.2017007427<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/panobinostat-united-states-withdrawn-from-market-drug-information/abstract-text/29296798/pubmed" id="29296798" target="_blank">29296798</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Farydak (panobinostat) [prescribing information]. Las Vegas, NV: Secura Bio, Inc; September 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/panobinostat-united-states-withdrawn-from-market-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30942181">
<a name="30942181"></a>Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncol</i>. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/panobinostat-united-states-withdrawn-from-market-drug-information/abstract-text/30942181/pubmed" id="30942181" target="_blank">30942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23950178">
<a name="23950178"></a>Richardson PG, Schlossman RL, Alsina M, et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. <i>Blood.</i> 2013;122(14):2331-2337. doi:10.1182/blood-2013-01-481325<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/panobinostat-united-states-withdrawn-from-market-drug-information/abstract-text/23950178/pubmed" id="23950178" target="_blank">23950178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25242045">
<a name="25242045"></a>San-Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. <i>Lancet Oncol</i>. 2014;15(11):1195-1206.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/panobinostat-united-states-withdrawn-from-market-drug-information/abstract-text/25242045/pubmed" id="25242045" target="_blank">25242045</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25377157">
<a name="25377157"></a>Sharma S, Witteveen PO, Lolkema MP, et al. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function. <i>Cancer Chemother Pharmacol</i>. 2015;75(1):87-95.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/panobinostat-united-states-withdrawn-from-market-drug-information/abstract-text/25377157/pubmed" id="25377157" target="_blank">25377157</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li></ol></div><div id="topicVersionRevision">Topic 100045 Version 206.0</div></div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
